These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 19173823

  • 41. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
    Pimentel FL, Bhalla S, Laranjeira L, Guerreiro M.
    Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
    [Abstract] [Full Text] [Related]

  • 42. A study of the combination of gemcitabine hydrochloride (LY188011) and cisplatin in non-small-cell lung cancer: 3-week schedule.
    Kunikane H, Kurita Y, Watanabe K, Yokoyama A, Noda K, Fujita Y, Yoneda S, Nakai Y, Niitani H.
    Int J Clin Oncol; 2001 Dec; 6(6):284-90. PubMed ID: 11828947
    [Abstract] [Full Text] [Related]

  • 43. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.
    Perng RP, Chen YM, Ming-Liu J, Tsai CM, Lin WC, Yang KY, Whang-Peng J.
    J Clin Oncol; 1997 May; 15(5):2097-102. PubMed ID: 9164223
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Inhibition of pancreatic cancer and potentiation of gemcitabine effects by the extract of Pao Pereira.
    Yu J, Drisko J, Chen Q.
    Oncol Rep; 2013 Jul; 30(1):149-56. PubMed ID: 23674070
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. [Apoptosis of the adriamycin-resistant leukemia cell line induced by the recombinant mutant human TNF-related apoptosis-inducing ligand combined with arsenic trioxide].
    Wang YR, Wen SP, Wang FX, Wen L, Yang BY, Yang JC, Zhang XJ, Yang SF.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1055-9. PubMed ID: 18928594
    [Abstract] [Full Text] [Related]

  • 51. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
    Comella P, Frasci G, Panza N, Manzione L, Lorusso V, Di Rienzo G, Cioffi R, De Cataldis G, Maiorino L, Bilancia D, Nicolella G, Natale M, Carpagnano F, Pacilio C, De Lena M, Bianco A, Comella G.
    J Clin Oncol; 1999 May; 17(5):1526-34. PubMed ID: 10334540
    [Abstract] [Full Text] [Related]

  • 52. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling.
    Gong JH, Zheng YB, Zhang MR, Wang YX, Yang SQ, Wang RH, Miao QF, Liu XJ, Zhen YS.
    Cancer Biol Ther; 2020 Apr 02; 21(4):332-343. PubMed ID: 31906826
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Role of dalteparin sodium on the growth of cancer cells and tumor-associated angiogenesis in A549 human lung cancer cell line and grafted mouse model.
    Rui Y, Wang D, Hu D, Huang L.
    J Cancer Res Ther; 2018 Dec 02; 14(Supplement):S985-S992. PubMed ID: 30539834
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI-H460 cells by repressing MAP kinase pathways and inflammatory mediators.
    Dai B, Ma Y, Wang W, Zhan Y, Zhang D, Liu R, Zhang Y.
    J Cell Mol Med; 2017 Oct 02; 21(10):2573-2585. PubMed ID: 28444871
    [Abstract] [Full Text] [Related]

  • 57. Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft.
    Kong M, Fan J, Dong A, Cheng H, Xu R.
    Acta Biochim Biophys Sin (Shanghai); 2010 Nov 02; 42(11):827-33. PubMed ID: 20978038
    [Abstract] [Full Text] [Related]

  • 58. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
    Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, Waud WR, Zhang X.
    Cancer Chemother Pharmacol; 2007 Feb 02; 59(2):183-95. PubMed ID: 16724239
    [Abstract] [Full Text] [Related]

  • 59. SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine.
    Zhao C, Yue B, Liu H, Sun C, Li W, Qu X.
    Toxicol Appl Pharmacol; 2012 Aug 01; 262(3):293-300. PubMed ID: 22617428
    [Abstract] [Full Text] [Related]

  • 60. Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.
    Guo L, Fan L, Ren J, Pang Z, Ren Y, Li J, Wen Z, Qian Y, Zhang L, Ma H, Jiang X.
    Int J Nanomedicine; 2012 Aug 01; 7():1449-60. PubMed ID: 22619505
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.